April 17, 2018
News & Publications
Press Releases
April 10, 2018
H3 Biomedicine to Present at 2018 American Association for Cancer Research Annual Meeting
Presentations highlight leadership in RNA splicing, a strategic focus area of the H3 cancer genomics product engine Read More »
April 3, 2018
H3 Biomedicine Publishes Comprehensive Genomic Landscape Analysis in Cell Reports Revealing Breadth, Frequency and Potential Disease-Driving Significance of Somatic Mutations in RNA Splicing Factor Genes in Multiple Types of Cancer
Novel findings underscore promise of H3 Biomedicine’s first-in-class splicing factor modulator H3B-8800 currently in Phase 1 clinical trial for patients… Read More »
March 19, 2018
H3 Biomedicine to Present at the BioCentury Annual Future Leaders in the Biotech Industry Conference
Read More »
March 6, 2018
H3 Biomedicine to Present at the Cowen Annual Health Care Conference
Read More »
February 20, 2018
H3 Biomedicine Preclinical Proof-of-Concept Data on First-in-Class Spliceosome-Modulator Therapy for Genomically Identified Patients with Hematological Cancers Published in Nature Medicine
H3B-8800 is first known investigational therapy to target RNA splicing factor mutations, highly prevalent in many hematologic cancers Initial data… Read More »In the Media
BioPharm Insight
H3 Biomedicine in active discussions for co-developing its cancer genomics programs – CEO
H3 Biomedicine is in talks with pharma companies to co-develop one or more of its Phase I drugs that are… Read More »
Boston Business Journal
H3 Biomedicine to Begin Trials of First-Ever Gene-Splicing Cancer Drug
Kendall Square-based cancer biotech H3 Biomedicine, created five years ago by Japanese drug firm Eisai, will bring its first drug… Read More »
PharmaVOICE
H3 Biomedicine’s Dr. Lihua Yu Honored in PharmaVOICE 100
In her position as VP, data science and information technology, at H3 Biomedicine, Lihua Yu, Ph.D., is driving the expanded… Read More »
Boston Business Journal
Foundation Medicine, H3 Biomedicine Partner to Develop Cancer Drugs
A partnership announced today between two Cambridge companies, Foundation Medicine (Nasdaq: FMI) and H3 Biomedicine, is further evidence of the… Read More »Scientific Publications
Genes & Development | February 7, 2018
The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action
Somatic mutations in spliceosome proteins lead to dysregulated RNA splicing and are observed in a variety of cancers. These genetic… Read More »
Nature Medicine | February 19, 2018
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers
Genomic analyses of cancer have identified recurrent point mutations in the RNA splicing factor–encoding genes SF3B1, U2AF1, and SRSF2 that… Read More »
Nature Communications | July 24, 2017
Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer
Muscle-invasive bladder cancer (MIBC) is an aggressive disease with limited therapeutic options. Although immunotherapies are approved for MIBC, the majority… Read More »
Nature Communications | May 25, 2017
Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A–SF3b complex
Pladienolide, herboxidiene and spliceostatin have been identified as splicing modulators that target SF3B1 in the SF3b subcomplex. Here we report… Read More »Media Inquiries
For all media interested in speaking to members of H3 Biomedicine’s executive/scientific team, or receiving further information about the company or pipeline, please forward your request to Liz Melone.
